Lessons and enlightments of health insurance drug renewal policy in some countries and regions

VernacularTitle:部分国家和地区医保药品续约政策经验及启示
Author: Xin-Ru HAN ¹ ; Kang-Ni ZENG ; Jia-Long TAN ; Jian WANG
Author Information

1. 武汉大学董辅礽经济社会发展研究院湖北武汉 430072
Keywords: Renewal; Risk-sharing agreement; Joint measurement; Price-volume agreement
From: Chinese Journal of Health Policy 2024;17(7):75-80
CountryChina
Language:Chinese
Abstract: Objective:Summarizing and analyzing the rules of access and renewal of drugs in Australia,Japan,South Korea,and Chinese Taiwan,this paper aims to provide experience for the improvement of China's policy on national drug reimbursement list renewal.Methods:Through literature review,expert interviews,and other academic methods,it compares the different experience of drug renewal policy from the perspectives of the type,content,and renewal period.Results:Internationally representative national or regional medical insurance drug renewal policies are broadly categorized into single-drug price-volume agreements,joint price-volume agreements,and efficacy-based risk-sharing agreements.Conclusion:It is recommended that China should introduce new content such as joint measurement for renewal of exclusive drugs,combination consideration of quantity,price,and effectiveness,risk-sharing agreement for renewal of non-exclusive drugs,and placing an upper limit on the rate of reduction for the first renewal in its medical insurance policy.